Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01015222 · ClinicalTrials.gov registry record · Phase 1
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 122
- Enrollment target
NCT01015222: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01015222 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 122 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (103% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01015222, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 122 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of dasatinib, bevacizumab, and paclitaxel with or without Methylnaltrexone that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.
Primary Outcome
MTD defined as the highest dose below any dose that has one third or more patients with dose limiting toxicities (DLT).
Interventions
- DRUG Bevacizumab
- DRUG Paclitaxel
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2009-11 |
| Est. Completion | 2021-05-27 |
| Phase | Phase 1 |
What the finished NCT01015222 record still lists
NCT01015222 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (103% higher).
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01015222 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01015222 about?
NCT01015222 is a clinical study titled "Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies". The goal of this clinical research study is to find the highest tolerable dose of the combination of dasatinib, bevacizumab, and paclitaxel with or without Methylnaltrexone that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.
What is the current status of trial NCT01015222?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 122 participants. The study started on 2009-11. Estimated completion is 2021-05-27.
What interventions are being tested in trial NCT01015222?
The interventions under investigation include: Bevacizumab (DRUG), Paclitaxel (DRUG), Dasatinib (DRUG).
Who is sponsoring clinical trial NCT01015222?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01015222's enrollment target sits among peer trials
122 475th of 2000 higher than 1,525 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia